Platinum Investment Management LTD Assembly Biosciences, Inc. Transaction History

Platinum Investment Management LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.8 - $1.74 $163,227 - $355,019	-204,034 Reduced 18.64%	890,736 $748,000
Q4 2022 Feb 13, 2023	SELL	$1.09 - $1.52 $387,558 - $540,448	-355,558 Reduced 24.52%	1,094,770 $1.42 Million
Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.34 $239,604 - $329,808	-140,944 Reduced 8.86%	1,450,328 $2.38 Million
Q2 2022 Aug 11, 2022	SELL	$1.35 - $2.29 $429,605 - $728,737	-318,226 Reduced 16.67%	1,591,272 $3.34 Million
Q4 2021 Feb 11, 2022	BUY	$2.13 - $3.46 $546,321 - $887,451	256,489 Added 15.52%	1,909,498 $4.45 Million

Q2 2021 Aug 11, 2021	BUY	$3.8 - $4.56 $843,178 - $1.01 Million	221,889 Added 15.5%	1,653,009 $6.41 Million
Q1 2021 May 13, 2021	BUY	$4.33 - $6.63 $2.64 Million - $4.04 Million	609,234 Added 74.13%	1,431,120 $6.58 Million
Q4 2020 Feb 12, 2021	BUY	$4.87 - $17.29 $2.91 Million - $10.3 Million	596,994 Added 265.46%	821,886 $4.97 Million
Q3 2020 Nov 13, 2020	BUY	$15.08 - $27.04 $1.05 Million - $1.89 Million	69,938 Added 45.13%	224,892 $3.7 Million
Q1 2020 May 15, 2020	BUY	$10.27 - $21.23 $1.59 Million - $3.29 Million	154,954 New	154,954 $2.3 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

Stay updated on Platinum Investment Management LTD with notifications on news.